Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D2.214 - Alpha-Amylase Inhibitors as Allergens in Wheat Flour Sensitivity
D2.213 - Unveiling Pitaya Pollen Allergenicity: A Case Study in Occupational Allergy
D2.215 - Retrospective evaluation of the outcome of 106 oral food challenges performed in 2017 to 2024
D2.216 - Sensitization to legumes after an occupational allergy produced by guar gum
D2.217 - A human monoclonal antibody displays promiscuous binding to multiple nsLTP allergens
D2.218 - ASSESSING THE DIAGNOSTIC VALUE OF SPECIFIC IgG4 IN KOREAN ADULT SHRIMP ALLERGY BASED ON SYMPTOM PRESENCE
D2.219 - An “egg-bird syndrome” in a 12-year-old male child
D2.220 - NsLTPs as Allergens in Pitaya and Hemp Seeds: A Case Study
D2.222 - Histamine intolerance is uncommon among Chinese patients reporting allergic reactions to shrimp
D2.223 - Implementing a liberated diet in food allergy management: Practical approaches and challenges from the TINA trial
D2.224 - Cross-tolerance to cashew by prophylactic sublingual immunotherapy with different tree nuts in Brown Norway rats
D2.225 - Fixed-Dose Oral Immunotherapy for High-Threshold Food Allergy: Efficacy and Safety in Real-World Practice
D2.226 - Optimised recovery of specific food allergens from challenging food matrices
D2.228 - Changes in temperature during allergic reactions to food in human volunteers
D2.229 - Hypersensitivity reactions associated with the use of food supplements containing propolis. Analysis of observations reported to the French National Agency for Food, Environmental and Occupational Health Safety (Anses)
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download